Supernus Pharmaceuticals, Inc. (SUPN) by event type
SUPN moves most on analyst downgrades — a median of +0.45% at 30 minutes across 23 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the SUPN overview →
How SUPN reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 881 of 2,717 | 20 | +0.17% | 50% | -0.80% |
| Analyst downgrades 441 of 2,603 | 23 | +0.45% | 52% | +1.22% |
| Rating reiterations 2,483 of 3,522 | 16 | -0.08% | 50% | +0.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how SUPN usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Rating reiterations → · SUPN overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Celyad Oncology SA - American Depositary Shares (CYAD) | 504 | 0.00% | 41% |
| DELMAR PHARMACEUTICALS (DMPI) | 504 | -0.13% | 38% |
| CORINDUS VASCULAR ROBOTICS INC (CVRS) | 503 | -0.65% | 37% |
| Teligent, Inc. (TLGT) | 502 | -0.17% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.